DVAX · As filed with the SEC
Dynavax Technologies income statement, by fiscal year
The statement as Dynavax Technologies presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Operations · USD thousands, except per-share amounts; shares in thousands
| USD thousands, except per-share amounts; shares in thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 |
|---|---|---|---|---|
| Revenues: | ||||
| Total revenues | 277,246 | 232,284 | 722,683 | 439,442 |
| Product revenue | 268,430 | 213,295 | 713,645 | 437,099 |
| Other revenue | 8,816 | 18,989 | 9,038 | 2,343 |
| Operating expenses: | ||||
| Cost of sales - product | 49,445 | 50,167 | 262,153 | 173,572 |
| Cost of sales - amortization of intangible assets | — | — | 0 | 0 |
| Research and development | 61,550 | 54,886 | 46,600 | 32,228 |
| Selling, general and administrative | 170,373 | 152,946 | 131,408 | 100,156 |
| Gain on sale of assets (Note 8) | 0 | (1,000) | (1,000) | (1,000) |
| Bad debt expense (Note 9) | 0 | 12,313 | — | — |
| Restructuring | — | — | — | 0 |
| Total operating expenses | 281,368 | 269,312 | 439,161 | 304,956 |
| (Loss) income from operations | (4,122) | (37,028) | 283,522 | 134,486 |
| Other (expense) income: | ||||
| Interest income | 36,464 | 31,993 | 7,912 | 140 |
| Interest expense | — | (6,757,000) | (6,732,000) | (11,176,000) |
| Interest expense | (6,794) | — | — | — |
| Sublease income | 5,014 | 7,577 | 7,685 | 7,735 |
| Loss on debt extinguishment (Note 11) | — | 0 | 0 | (5,232,000) |
| Change in fair value of warrant liability (Note 14) | 0 | 0 | 1,801 | (49,354) |
| Other | 293 | (152) | 111 | 922 |
| Net income (loss) before income taxes | 30,855 | (4,367) | 294,299 | 77,521 |
| Provision for income taxes | (3,546) | (2,022) | (1,143) | (808) |
| Net income (loss) | 27,309 | (6,389) | 293,156 | 76,713 |
| Undistributed earnings allocated to participating securities | 0 | 0 | (283) | (4,569) |
| Preferred stock deemed dividend | — | — | — | 0 |
| Net (loss) income allocable to common stockholders, basic (in USD per share) | 27,309 | (6,389) | 292,873 | 72,144 |
| Net income (loss) per share allocable to common stockholders | ||||
| Basic (in USD per share) | 0.21 | (0.05) | 2.32 | 0.62 |
| Diluted (in USD per share) | 0.20 | (0.05) | 1.97 | 0.57 |
| Weighted-average shares used in computing net income (loss) per share allocable to common stockholders: | ||||
| Basic (in shares) | 130,047 | 128,733 | 126,398 | 116,264 |
| Diluted (in shares) | 133,344 | 128,733 | 150,797 | 133,006 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.